BRAJTENShTAJN Verner (CH),БРАЙТЕНШТАЙН Вернер (CH),FJuRE Paskal' (FR),ФЮРЕ Паскаль (FR),DZhEJKOB Sandra (FR),ДЖЕЙКОБ Сандра (FR),MANLI Pol Uill'jam (CH),МАНЛИ Пол Уилльям (CH),BRAJTENSHTAJN VERNER,FJURE PASKAL,DZHEJKOB SANDRA,MANLI POL UILLJAM
申请号：
RU2008137927/04
公开号：
RU0002445309C2
申请日:
2008.09.24
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds of formula (I), treating a disease related to proteinkinase activity inhibition, specifically cancer, particularly leukaemia, a method of treating such disease and a method of producing such compounds. In formula (I) R1 represents hydrogen, lower alkyl, lower alkoxy-lower alkyl； R2 represents lower alkyl substituted by one or more identical or different radicals R3, cyclohexyl, cycloheptyl, benzcyclopentyl(indane), benzcyclohexyl, penta-, hexa- or heptamerous heterocyclic system with one or two heteroatoms specified in a group consisting of nitrogen and oxygen which can be unsaturated or completely saturated, and is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl or oxo； phenyl which is unsubstituted or substituted by one or two substituted specified in a group consisting of lower alkyl, lower alkoxycarbonylpiperidino-lower alkyl, N-lower alkylpiperazino-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower alkoxy, 1H-imidazolyl-lower alkoxy, lower alkoxycarbonyl, lower alkylcarbamoyl, amino mono- or disubstituted lower alkyl, morpholino, lower alkylsulphonyl, halogen and benzoyl； and the value R3 is specified in the patent claim, or R1 and R2 together represent alkylene with four, five or six carbon atoms, optionally mono- or disubstituted by lower alkyl； hexamerous heterocyclic system with one or two heteroatoms specified in a group consisting of nitrogen which can be unsaturated or completely saturated, and is unsubstituted or substituted according to the patent claim, R4 represents hydrogen or lower alkyl.EFFECT: preparing the composition for treating a disease related to proteinkinase activity inhibition.5 cl, 99 exИзобретение относится к новым соединениям формулы (I), где для лечения заболевания, которое связано с ингибированием активности протеинкиназы, особенно опухолевого заболевания, в частности лейкемии, способу лечения такого заболевания и способу получения соед
